Ray Blanco’s : “What This CEO Says on Nov.7, 2015 Could Revolutionize Modern American Medicine…”

Solving the latest teaser pitch from Agora Financial's FDA Trader

By Travis Johnson, Stock Gumshoe, October 27, 2015

I know I’ve said this before, and sometimes it’s a lie: I’m going to try to keep this one brief.

Agora Financial’s FDA Trader service has a new pitch out — which normally might not get that much attention, since everyone is suddenly terrified of biotech stocks after a brutal month or two — but the promise is not just that a drug will get approved and make you rich… the promise is that this company will “revolutionize modern medicine.”

So what are they talking about? Well, the short answer is, “a cure for Alzheimer’s Disease.”

Which, depending on how long you’ve been investing in or reading about healthcare stocks, will either make you want to reach for your wallet or hide under your desk. Alzheimer’s Disease is by far the largest and most lucrative market that is underserved by pharmaceuticals — and the constant search for new treatments for this awful, high volume disease that has been a money pit for pharmaceutical companies. The disease is challenging and still very poorly understood, the only treatments available now are disappointing and help just some of the patients with some of their symptoms, and any new drug faces extraordinary challenges and very expensive clinical trials.

But, of course, if anyone does come up with a cure or a preventive for Alzheimer’s Disease that’s safe and approvable, they could make a whole boatload of money. So we see pitches about tiny biotech companies that have a cure for Alzheimer’s every now and then.

That’s what this one is today — the ad is for FDA Trader from Agora, edited by Ray Blanco (who has been the default editor of most of their technology-focused newsletters for many years — this newsletter used to be helmed by Paul Mampilly, but he moved a couple buildings down to work at Stansberry)… so what are we told about this secret little company?

Well, here’s why Gumshoe readers are asking about this one:

“On Saturday, November 7, a CEO you’ve likely never heard of will step up to the podium….

“Standing at that podium, he’ll be in front of the most respected names in his industry.

“When he starts speaking, he could change forever everything we think we know about one of the most frightening diseases in world history.

“What he has to say could revolutionize modern medicine for reasons I’ll show you here today.

“The market frenzy his comments create could also make you incredibly wealthy.

“That’s because, when the markets open on Monday, November 9, the stock of the company this CEO leads could explode rapidly higher.

“If this CEO’s presentation on November 7 goes as well as I expect, starting Monday, November 9, you could take part in an epic share price explosion.

“I’m talking about the chance at gains of as much as 2,150% or more as this tiny company rockets from under $9.00 to $200 and beyond.”

So, 2,150% gains — nice, right? And he implies that, while it “may take time,” the huge gains will start right away on November 9. Assuming, of course, that he’s right about what this CEO is going to say.

Some more clues? Well, let me give you another wee taste of the hype first:

“If You Buy Just One Stock For the Next Year, This is the One

“This CEO’s company might control what we come to view as the breakthrough of the decade.

“Over 5 million Americans, in fact, suffer as I write from the disease this company aims to treat.

“Actually, ‘treat’ isn’t the right word.

“If this company’s trial results continue to progress as well as early reports indicate, this company’s breakthrough could actually ‘reverse’ the disease.

“What we’re dealing with here… for the first time in modern medical history… is the potential ability to take a disease with no cure and no good treatment…

“… and stop it in its tracks. That’s the big picture.

“This advance, it goes without saying, could be unprecedented. No one has ever seen anything like this before.”

OK, OK — enough drooling! I know, I know, it’s supposed to make us filthy rich, and make us feel good about owning shares of the company that finally eradicates the scourge of Alzheimer’s… so what is it?

Final clues for you — don’t worry, I won’t make you sift through the whole ad (you can see it here if you want the water torture version), but we do need to confirm that this company is the one I think it is. The clues:

“For the first time in history, we may have an AD drug on our hands that stops and reverses the symptoms of the disease.

“Here’s the important point:

“Phase 2A testing of this drug took a small group of patients with mild-to-moderate Alzheimer’s symptoms and put them on the drug for 36 days.

“83% of patients had a positive response, and the cognitive skills / memory testing of those patients increased 4x over the current ‘standard of care’ drug.

“Keep in mind, this preliminary Phase 2A data didn’t have optimized dosing. The treatment also wasn’t administered long-term.

“For a small Phase 2A study, this was a profound and fascinating result:

“83% of those who took the drug saw a benefit.

“And improvement in memory function was a robust 4x increase over the current standard drug.”

So the basic spiel is, this company is releasing more detail from their Phase 2A trial for some kind of Alzheimer’s Disease drug, and Blanco thinks it will show continued success and the stock will rocket forward as they progress into Phase 3 and move toward determining whether the drug is really safe and effective on a large scale, making us all gazillions of dollars. But, of course, you’ll “miss out” if you don’t subscribe to his newsletter ($1,600, please) before the CEO gives his presentation in a couple weeks.

And the stock? Thinkolator sez this is one we’ve seen similarly teased many, many times: Anavex Life Sciences (AVXLD on the OTCQX as of today, though it will begin trading on the Nasdaq tomorrow at AVXL), standard-bearer of the Alzheimer’s hopefuls in the junior biotech space for nearly a decade now.

Yes, Anavex will be reporting some results on November 7 at a conference — though it won’t be the CEO, it will be the principal investigator from Australia reporting the results. This will be an updated version of the results they announced a few months ago, since the first part of the two-part study has now been fully enrolled and they have more data. This is largely a dose-finding study, though they’re also hoping for some positive efficacy results and, of course, a lack of surprise safety concerns.

I am not a biotech investor, and not an expert on the disease or the drug, but my impression is that it’s a measure of how desperate we are for any kind of hope in Alzheimer’s Disease that this trial is generating so much attention — the results in July, as I saw it, were that 10 out of 12 patients showed memory improvement, without any kind of placebo arm. It’s hard enough to run a good clinical trial without a double blind placebo, but doing one in areas of memory and cognition, where you’re counting on the interpretations of patients and other human beings to judge whether there’s improvement, strikes me as not very powerful. That’s not necessarily a criticism of the company, they’re still trying to determine what dosing and regiment has the best chance of working and they will certainly be required to have huge double-blind trials before they get approval on this drug — to say nothing of part B of this current trial, which will not be complete for at least a year… it’s just a reminder that, in Alzheimer’s especially, it’s important not to get your hopes up too quickly.

The drug is Anavex 2-73, which we’ve certainly mentioned a few times — it has been the highest profile “hopeful” drug for Alzheimer’s among the junior biotechs for a long time. And it’s history tells you something about how hard it is to develop drugs for this disease — they initially thought they’d be filing for an IND and starting their Phase 1 trials for Anavex 2-73 back in 2008. Ray Blanco’s former colleague pitched this one back in December of last year, too, and he and several other newsletters have pitched it as the “end of the Grey Plague” or the “next blockbuster” for almost as long as Stock Gumshoe has existed (we started publishing in 2007, FYI).

Anavex does have other drugs in development, too — though they jump around some as hope and potential shifts, and they don’t appear to currently be spending money on any of the other drugs right now, it’s all about Anavex 2-73 and Anavex Plus (which is just Anavex 2-73 plus Aricept, the current “standard of care” drug for Alzheimer’s symptoms).

And, as you might expect, the company does not have the capital to run a multi-year Phase 3 trial (assuming they eventually get that far) with hundreds of patients — but it has become more of a mainstream stock this year as they reported good Phase 1 results, started Phase 2, and applied for uplisting to Nasdaq, with much higher trading volume and a rising price… so they should at least be able to raise money on better terms. They also have an agreement in place with their big institutional investor, Lincoln Park Capital, that could bring in another $50 million if I’m reading the terms right — presumably Lincoln park also gets some kind of sweetener in the form of warrants or pricing or something, I haven’t checked.

The presentation on the trial will be at a conference on clinical trials in Alzheimer’s Disease in Barcelona in early November, Anavex’s press release about it is here. Judging from past Alzheimer’s trials I’ve seen over the years, my guess would be that they’ll require another Phase 2 trial or maybe 2b/3a trial if you want to start parsing that, which would probably not start until next year sometime, and they’d require a long Phase 3 trial of a couple years, at least. And, of course, given the past performance of Alzheimer’s Disease drugs and the continued lack of real detailed understanding about the disease and its causes, I’d assume we should probably continue to give them a low number in the “probability of approval” department.

That’s said, I reiterate, as someone who is not not not an expert on this drug, this disease, or even this company — but the symptom-treating drugs that have been developed, have, in the rare cases where they’ve made it through to approval, taken a loooong time. The reward is high — Aricept, despite the fact that it really isn’t a “cure” for Alzheimer’s and doesn’t reverse the progress of the disease, still had peak sales well into the billions before it went off patent a few years ago — so we should expect the risk to be high, too.

For me, the biggest risk is that we’re talking about a tiny company riding high on sentiment and still probably a year or more from entering the most expensive phase of drug development (it’s up dramatically on the year, though that followed a four-year decline from the days when the IND was first being talked about for Anavex 2-73 — AVXL is up a couple hundred percent this year, and is down about 90% since the 2008 highs). I may be a bit too cynical about this one, since I’ve written about the “promise” of a real disease-modifying drug for Alzheimer’s Disease at least a half dozen times over the last seven years, and it’s always been about Anavex, and they’re still just in a Phase 2 trial with 32 patients. But that said, the stock has clearly performed well this year because of the new attention, the progress into early stage trials and lack of bad news and, probably more than anything else, the public attention and massive size of the end market.

If past Alzheimer’s drug hopes are any indication, there are four scenarios I could guess at: A, it could collapse on the next news release or sometime in the current trial because of bad news; B, it could consume a couple hundred million dollars running a big phase 3 trial and fail to show good results because of poor safety or lacking efficacy, and see the share price drop on bad news and capital raisings over several years; C, it could attract a suitor if they get “phase 3 ready” and get bought out or partnered to cut costs, driving the shares up further; or D, it could, maybe sometime early in the 2020s after another 5 years of clinical trials, eventually get approved and be the cure everyone’s looking for. My guess is “B” … but, as I noted above, I may be too cynical on this one and it has certainly gotten some folks excited so far this year.

So that’s what we’ve got for you today — whaddya think? Willing to bet on Anavex this time around? Let us know with a comment below.

P.S. I should note that our favorite biotech columnist, Dr. KSS, has been unimpressed by Anavex in the past — he last commented on it here, I think.


Irregulars Quick Take Paid members get a quick summary of the stocks teased and our thoughts here. Join as a Stock Gumshoe Irregular today (already a member? Log in)

99
Share your thoughts...

avatar
35 Comment threads
64 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
50 Comment authors
Sun Sa1dozzerGr8Full!who nozetncbg Recent comment authors

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Ben
Guest
Ben

A year ago this month, you recommended EverBank’s BRICS CD, a three-year commitment. After a year, the CD is ‘limping’ along, having earned a grand total of $3.12. Any comment?
Ben

Add a Topic
1340
Mike
Guest
Mike

You are wrong on this one.

Chuck
Guest
Chuck

I’d have to agree.

Option A is all but ruled out at this point (for the 11/7 data at least).

Option B is unlikely because assuming 11/7 data confirms the 7/22 data you already have something with more efficacy than standard of care and one of the biggest unmet needs in medicine. Bigger trials will only confirm this and safety has been clean thus far.

Option C, most likely what will happen.

Option D, would be even better than option C I just don’t know if I’m that patient!

Richard
Guest
Richard

One can delay the onset of dementia by learning, a new language, playing high level chess, learning to lay a new musical instrument, doing crosswords puzzles, doing sodoku, not smoking, not drinking excessively. Donepezil is now off patent and should cost about $30 per month.

The nun study indicates that on autopsies nun’s may have severe Alzheimer’s disease but not on cognitives tests done shortly before death.

Add a Topic
2866
Drano
Guest
Drano

That is incorrect. Although exercise does seem to help people with Alzheimer’s delay some of the degeneration, there are plenty of people who remained mentally active, exercised, ate right — and still got Alzheimer’s. Those studies claiming that learning new things delays onset have been discredited many times. Claiming that lifestyle can prevent or delay Alzheimer’s gets dangerously close to a “blame the victim” mentality. Having known several people who have gotten this horrible disease because of their genetics but had very healthy lifestyles, I find it offensive to see these unscientific untruths repeated — and, oddly enough, they are… Read more »

Richard
Guest
Richard

The nun studies indicate the nuns on Autopsy studies have Alzheimer’s, but on cognitive testing there are no indications of dementia. “Those studies claiming that learning new things delays onset have been discredited many times” is not correct.
Richard

chibana
Irregular
chibana

Team,
$AVXL is my one regret stock for 2015. Purchased shares for $.50 sold at $.88. Trading today at $9.60 (split adjusted). $200 is probably a stretch but maybe $20 isn’t near term with good results. Track record hasn’t been good with many attempts to treat Alzheimer’s Disease but that of course doesn’t mean this treatment won’t work. Perhaps the news is already priced in and if the results don’t impress share price will fall like a stone. Time will tell as always. TIB.
V/R
Tom

Add a Topic
5971
Add a Topic
2866
stevemack70
Member

I did a similar thing. B .63 S .94. Never looked back until this article caused me to. Not the first time I wasn’t patient enough and probably won’t be the last.

oldbob
Guest
oldbob

I’m surprised that the CEO in their pitch is that short. Most people would step up to a lectern and maybe stand on a podium.

Add a Topic
899
arch1
Member

oldbob You just hush now….yur not sposed to point out such things in those overpriced promises. I lust after 2150% profit but I can PROMISE 9723% profit if you just invest one penny in something that doubles every day for 90 days or possibly less. I just have no idea what could do that or does anyone,,, in what causes alzheimers,,,except you generally have to live to old age to get it. BTW you could probably get “some” improvement in 90% of the patients you gave a glass of water and a little attention,,,listening to them. IMHO fa

Add a Topic
540
jonee
Member
jonee

AVXL- What arch said above 🙂

sheila225
Member
sheila225

Just a thought-
Based on the study protocol, and the FDA Guidance issued in 2013 – its possible that they may have some early (Part B) data that demonstrates an improvement (even a slight one) in the cognitive function of patients with “early stage disease”. This could trigger (based on the Guidance) the FDA to permit an accelerated approval path. See the link below
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf

The inclusion criteria for the study lists “Diagnosis of Probable AD” and suggests that this approach is part of their clinical strategy.

Add a Topic
3022
Add a Topic
3022
takeprofits
Guest

The question that doesn’t seem to get asked is, what has changed in our lifestyles, diets, environment etc.over the past 100 years or so that could be a “trigger” for the development of such horrible diseases as Alzheimers. I question whether the answer lies in some magical drug that will cure the disease as opposed, as most drugs do, merely controlling symptoms to some degree. Far too much money is spent looking for “cures” that can be treated at a profit as opposed to searching for CAUSES that can be prevented. I remember decades ago reading about researchers concluding that… Read more »

Add a Topic
3397
Add a Topic
501
BJI
Guest
BJI

At what age does Alzheimers typically begin showing symptoms?
What was life expectancy 100 years ago? What is it now?
Isn’t “Old Age” the primary cause of dementia including Alz.?

Patricia
Member

BJI, has anyone bothered doing a comprehensive study comparing apples to apples: the RATE of dementia in those who reached advanced age in the past, to those who reach it now? Of course people are living longer – far fewer work accidents, fewer war deaths, less starvation and infectious disease, and the ability of doctors to do basic plumbing like bypass surgery. My own recall of people I’ve known is that far fewer of those who reached their 80s thirty or forty years ago developed dementias of any sort. Myron is correct – our poisoned environment and food supply is… Read more »

Add a Topic
6225
dcohn
Member

Perlmutter claims it is based on diet.http://www.perlmutterfoundation.org/

invest405
Member
invest405

I have 2 cases of near and dear of “early onset” in my inner circle. Both were 52 at the time of diagnosis and 5 years later – they are both very ill. I think we are finding that “early onset” is more normal these days than was thought before and that the numbers are increasing. A bit like autism.

Deep
Guest
Deep

When Dr. Altzeimer first reported his findings he was referring to “pre-senile” dementia in patients. Over time we have begun to shun the word “senile” and today all dementias seem to be called Altzeimer’s Dementia. Just some historical background.

Hupitat
Guest
Hupitat

We are what we eat. Why cows have a ‘madcow’ MD? Because they were eating (feed) something they should not be eating. Getting fungi (the fungi we can’t even eat) in our brain eating something we should not. Every one of us genetic make up is pretty unique and reacts differently every external factor. As a light colored skin (born in Northern Europe) I got melanoma just in 5 years after moving to Australia. I wore 30+ sunblock every day. Regardless precautions in my behalf, my skin was under relentless sun rays. Aboriginals have no problems with a sun. Maybe… Read more »

Add a Topic
1270
Add a Topic
5916
Gary J.
Guest
Gary J.

I haven’t found any underarm deodorants that don’t have aluminum in them. Do you know of any? I think I have even seen it in some vitamins but don’t ask why.

Add a Topic
5399
Joe B
Guest
Joe B

Tom’s of Maine (www.tomsofmaine.com) is one deodorant that has no aluminum unless it has recently been changed. Don’t think so. I’ve been suspicious of aluminum cookware as well.

stan
Irregular
stan

Yes, I get Tom’s at Walmart. Aluminum-free deodorant and fluoride-free toothpaste.
Might work, besides I like the products generally.

Sten L.
Guest
Sten L.

I am also vary of the aluminum and have used a $1.00
box of baking soda. Just stick 2 moist fingers
in the box after shower and wipe in arm pit.
Seems to last all day under most conditions

Add a Topic
5916
Lorraine S.
Member
Lorraine S.

Gary,
Try Primal Life Organics and Real Purity deodorants. They are excellent and contain only natural and organic ingredients. Both can be ordered online. Real Purity deodorant is also carried at some Whole Food Stores.

Ponce
Guest
Ponce

I read about a doctor whose very bright husband developed Alzheimer’s. After consultation with experts but no improvement, she did her own research and found virgin coconut oil as excellent food for the brain. The husband took at least 2 table spoons a day and in 37 days his symptoms was gone. The husband was able to go back working and made virgin coconut oil as his daily regimen. Of course no Pharma would be interested in this being a natural substance not patentable.

Add a Topic
359
Add a Topic
359
dcohn
Member

The mct oil in coconut oil is supposedly what helps. See Perlmutter.

Add a Topic
359
Add a Topic
359
stan
Irregular
stan

I believe this woman/doctor was and maybe is a professor at Yale U. I think I read this about 5 yrs ago

kristen mower
Guest
kristen mower

Mary Newport is the author of that book. Very good…I think her husband went down hill later but it certainly gave him longer time.

Gr8Full!
Member

Different Brain Regions are Infected with Fungi in Alzheimer’s Disease
http://www.nature.com/articles/srep15015 Best2ALL!-Ben

Add a Topic
2866
Patricia
Member

That was a great find Ben which I saw impressed even Dr. KSS. Cause or effect? I was once told about a personal remark by a surgeon to his patient that he found extreme parasite infestations in most of the cancer patients he operated on – if true, is that cause or effect? Why not both? I’ve seen some remarkable recoveries from serious illnesses in people who used herbs to kill their parasites, and in people who tried ketogenic diets (a diet which, in theory, would starve and kill fungi). If a body is being overwhelmed by a combination of… Read more »

Add a Topic
3932
Add a Topic
3397
Add a Topic
5198
John
Guest
John

I was telling people on here months ago to check out Anavex.. I have made some good money on this and if they get to phase $15 I still own shares and benefitted by their 1-4 stock split.. They are on the right track…

Add a Topic
5971
Gui_
Member
Gui_

Good job John, were you one of the ones in the discussion on KSS’ threads back in July? Unfortunately I left way to much money on the table bailing before the split, once again way to keep the faith. Here’s a repost of mine some might still find useful. RE: AVXL DD post on Investorshub by jbem777 one od 4 “picks” still current first posted on 3/25/2015 “jbem777 Wednesday, 03/25/15 10:46:44 AM Re: None Post # of 7037 AVXL DD- All you need to know Anavex (AVXL) http://www.anavex.com/ Here is some brief DD. Fully reporting OTC. Market Cap: Only $11… Read more »

Add a Topic
229
Add a Topic
229
Add a Topic
229
john
Guest
john

AVXL is at $9.70 will be at $15 when it gets to phase 3 I have beenin and out of this stock since it was .17 and I kept telling everyone about it.. now it’s paying off much more..

Add a Topic
5971
Gr8Full!
Member

AVXL-The terrible trio Agora, Lincoln Park and Maxim Kolbert has pump-and-Dump claws into Anavex per Adam Feuerstein Best2U-Ben

Add a Topic
6137
Add a Topic
4185
Add a Topic
2536
john
Guest
john

THey are late comers to this stock.. It’s been on the radar for two years…

Add a Topic
5971
Gr8Full!
Member

NOURISH AD is a clinical research study evaluating the safety and effectiveness of an investigational drug for mild to moderate Alzheimer’s disease. Study volunteers will be monitored closely by their study doctor. http://www.ipsresearch.com/trials/accera-nourish-ad-study/ I believe this is the trial that is using palm and coconut oil extracts Best2ALL!-Ben

Add a Topic
2866
Add a Topic
370
Add a Topic
359
Gr8Full!
Member
Gui_
Member
Gui_

Uplisting brings more institutional exposure

as well as more shorts wearing big boy pants,

good luck to all here that are in Anavex.

Vitt
Guest
Vitt